Published in Cancer Discov on March 26, 2013
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 2.65
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res (2015) 2.12
Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist (2013) 2.04
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist (2014) 1.71
Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov (2014) 1.61
Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol (2015) 1.24
The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med (2013) 1.18
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12
The evolving genomic classification of lung cancer. J Pathol (2014) 1.08
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res (2015) 1.07
The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers (Basel) (2015) 1.06
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun (2014) 1.05
Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol (2013) 1.03
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol (2016) 1.01
Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch (2014) 1.00
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. Onco Targets Ther (2014) 0.96
Lung cancer in the era of precision medicine. Clin Cancer Res (2015) 0.96
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) (2015) 0.93
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer (2014) 0.92
Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. Front Oncol (2014) 0.91
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res (2014) 0.90
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88
Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci (2016) 0.88
Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget (2015) 0.87
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget (2014) 0.87
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. Front Oncol (2014) 0.87
Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget (2015) 0.86
Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun (2015) 0.85
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer (2015) 0.84
A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid (2014) 0.84
Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med (2015) 0.84
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer (2015) 0.83
Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res (2015) 0.83
Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer (2014) 0.83
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol (2016) 0.83
Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience (2016) 0.82
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw (2014) 0.82
Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget (2015) 0.82
Recent advances in personalized lung cancer medicine. Per Med (2014) 0.82
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther (2016) 0.82
The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther (2015) 0.81
Advancing clinical oncology through genome biology and technology. Genome Biol (2014) 0.81
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chin J Cancer (2015) 0.81
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med (2015) 0.81
Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med (2015) 0.81
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol (2014) 0.80
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn (2016) 0.80
New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics (2016) 0.79
Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol (2013) 0.79
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol (2016) 0.79
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. Eur J Med Chem (2016) 0.79
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol (2015) 0.79
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget (2016) 0.78
The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. PLoS One (2015) 0.78
The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol (2014) 0.78
Fluorescence in situ hybridization in surgical pathology: principles and applications. J Pathol Clin Res (2017) 0.78
Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol (2016) 0.77
NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget (2016) 0.77
The new kid on the block: RET in lung cancer. Cancer Discov (2013) 0.77
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. Oncotarget (2016) 0.76
Personalized medicine: Special treatment. Nature (2014) 0.76
Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine? Transl Lung Cancer Res (2015) 0.76
Genomics driven-oncology: challenges and perspectives. BMC Cancer (2015) 0.76
RET-targeting molecular stratified non-small-cell lung cancers. Transl Lung Cancer Res (2013) 0.76
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. J Pers Med (2016) 0.76
Novel kinase fusion transcripts found in endometrial cancer. Sci Rep (2015) 0.76
RET mutations in neuroendocrine tumors: including small-cell lung cancer. J Thorac Oncol (2014) 0.76
Cabozantinib for progressive metastatic medullary thyroid cancer: a review. Ther Clin Risk Manag (2014) 0.75
KAOS: a new automated computational method for the identification of overexpressed genes. BMC Bioinformatics (2016) 0.75
The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data. PLoS One (2015) 0.75
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. Curr Oncol Rep (2017) 0.75
From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience. Lung Cancer Manag (2014) 0.75
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. Oncotarget (2016) 0.75
KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas. Diagn Pathol (2015) 0.75
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nat Commun (2016) 0.75
AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckl) (2015) 0.75
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discov (2017) 0.75
The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther (2015) 0.75
Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep (2017) 0.75
1p/19q codeletion and RET rearrangements in small-cell lung cancer. Onco Targets Ther (2016) 0.75
Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Res (2016) 0.75
Breaking down RET breakpoints in lung adenocarcinoma. J Thorac Oncol (2014) 0.75
Lung Cancer Biomarkers. Hematol Oncol Clin North Am (2017) 0.75
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res (2016) 0.75
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann Oncol (2016) 0.75
CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. BMC Med Imaging (2017) 0.75
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. Yonsei Med J (2017) 0.75
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. F1000Res (2016) 0.75
A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol (2015) 0.75
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab (2017) 0.75
Molecular Testing of Lung Cancers. J Pathol Transl Med (2017) 0.75
EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases. Cancer Res (2017) 0.75
Targeting RET-rearranged lung cancers with multikinase inhibitors. Oncoscience (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
The cancer genome. Nature (2009) 23.13
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2011) 4.15
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol (2009) 3.54
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol (2013) 2.40
TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 2.05
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res (2012) 2.04
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res (2012) 1.56
RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol (2003) 1.55
The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene (1999) 1.53
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.25
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res (1998) 1.05
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
The NIH Human Microbiome Project. Genome Res (2009) 24.61
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics (2009) 12.01
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Genome-wide association studies of 14 agronomic traits in rice landraces. Nat Genet (2010) 8.75
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
High-throughput genotyping by whole-genome resequencing. Genome Res (2009) 5.74
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Physical activity and weight gain prevention. JAMA (2010) 5.27
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol (2006) 4.97
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 4.77
Discovering motifs in ranked lists of DNA sequences. PLoS Comput Biol (2007) 4.40
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev (2006) 4.06
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys (2010) 3.87
Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A (2004) 3.82
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res (2011) 3.56
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology (2009) 3.30
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol (2011) 3.05
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res (2011) 3.03
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol (2008) 2.92
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med (2006) 2.83